Journal Healthcare Treatment Development (JHTD) ISSN 2799-1148 · Vol. 4, No. 01 (2024) · pp. 122-129
Research Paper

Recent advances in understanding and treating Parkinson's disease

Mohd Altaf Dar1, Afshana Qadir2, Zulfkar Qadrie3, Humaira Ashraf4
  1. 1 Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.
  2. 2 Nursing Tutor, Government College of Nursing Baramulla, India.
  3. 3 Department of Pharmacology, Government Medical College, Baramulla, India.
  4. 4 Department of Animal Nutrition, SKUAST-K, Srinagar, India.
  5. * Corresponding author: Mohd Altaf Dar, daraltaf490@gmail.com
Received27 February 2024
Revised3 May 2024
Accepted11 May 2024
Published25 June 2024
DOIhttps://doi.org/10.55529/jhtd.43.34.41
LicenceCC BY 4.0
PDFDownload PDF

Abstract

Background: Neurodegenerative illness that is characterised by the loss of dopaminergic neurons in the substantia nigra. Because its global prevalence keeps going up, there’s a need for fresh, updated synthesis of what’s new in pathophysiology, diagnostics, and treatment options, maybe also how clinicians should think about them. Objective: This review, more or less, aims to look at the current landscape of PD pathophysiology, and then check out emerging diagnostic modalities, then summarise how pharmacological and non-pharmacological treatment strategies are changing. It also tries to include a set of more novel experimental angles, not only the usual stuff. Methods: For the methods, we carried out a narrative review using published literature that covers PD pathogenesis, genetic mutations, diagnostic technologies, and therapeutic interventions. We tried to spot key trends, and then connect those findings with what they might mean for real-world clinical management , over time. Results: In the results section, the big central pathogenic feature is the alpha-synuclein aggregation that forms Lewy bodies. On the genetic side, mutations in SNCA, LRRK2, PARK7, PINK1, and PRKN are tied to familial forms and they help explain molecular disease mechanisms. For diagnostics, progress includes PET and SPECT neuroimaging, along with cerebrospinal fluid markers and blood-based biomarkers, these together support earlier identification and more precise phenotyping. On therapy, levodopa and dopamine agonists are still treated as first-line pharmacological choices; deep brain stimulation, DBS, acts as a useful adjunctive non-pharmacological intervention. Meanwhile, gene therapy and stem cell based approaches are still more investigational, but they look promising for what could come next. Conclusion: So in the end, recent research has pushed forward the understanding of PD pathophysiology a lot, and it also broadened the available diagnostic and therapeutic options. The overall idea is that combining biomarker-guided diagnosis with emerging disease-modifying therapies could really help, and it holds promise for better long-term outcomes in PD patients, though it’s not fully settled yet.

Keywords: Parkinson’s Disease, Bradykinesia, Rigidity, Lewy Bodies, Gene Therapy, Biomarkers.

1. INTRODUCTION

Tremor, bradykinesia (slowness of movement), rigidity (muscle stiffness), and postural instability are some of the motor symptoms that are associated with Parkinson's disease (PD), which is a neurodegenerative disorder that progresses over time and affects millions of people across the world who are affected by it. In his key book known as "An Essay on the Shaking Palsy," which was published in 1817, James Parkinson was the first person to define the disorder. Since then, it has been acknowledged as the second most common neurodegenerative disease, following Alzheimer's disease. The predominant cause of Parkinson's disease (PD) is the slow degradation and loss of dopaminergic neurons in the substantia nigra, which is an essential part of the brain that is involved in the regulation of movement [1] , [2], [3], [4], [5]. Several factors, both genetic and environmental, are involved in the development of Parkinson's disease, which is a complicated condition. Intracellular inclusions that are predominantly formed of aggregated alpha-synuclein protein are known as Lewy bodies, and their presence is a characteristic feature of the disease pathogenesis. Normal cellular activities are disrupted as a result of the aggregation of alpha-synuclein and its misfolding, which ultimately results in the death of neurons. The bulk of Parkinson's disease diagnoses are made up of idiopathic instances; nevertheless, genetic abnormalities have been found in numerous genes that are connected with familial forms of the disease. All of these proteins, including SNCA (which encodes alpha-synuclein), LRRK2 (Leucine-rich repeat kinase 2), PARK7 (DJ-1), PINK1 (PTEN-induced kinase 1), and PRKN (Parkin), have made significant contributions to our knowledge of the molecular mechanisms that underlie Parkinson's disease (PD) [5], [6], [7]. Gaining an understanding of the pathophysiology of Parkinson's disease has been essential to the development of techniques for diagnosis and treatment. The findings of recent studies have extended our understanding of the ways in which alpha-synuclein aggregates play a role in neurodegeneration, as well as the ways in which genetic and environmental factors interact to influence the start and course of disease. The formation of diagnostic tools and treatment techniques has been influenced by this body of knowledge; yet, there are still obstacles to overcome in terms of completely unravelling the causes of disease and converting this understanding into interventions that are effective [7],[8], [9], [10].

2. RELATED WORK

Over the past several years, there has been a substantial advancement in the study of Parkinson's disease, particularly with regard to the function of alpha-synuclein in the medical pathology of the disease. The aggregation of alpha-synuclein into Lewy bodies is a characteristic that is characteristic of Parkinson's disease (PD). Studies have demonstrated that this aggregation causes synaptic function to be disrupted and leads to the death of neurons. The identification of mutations in the SNCA gene, which encodes alphasynuclein and is related with early-onset Parkinson's disease, has provided support for the understanding of the role that alpha-synuclein plays with regard to disease progression [10], [11], [12], [13]. In addition, other genetic mutations, such as those found in LRRK2 and PINK1, have been associated with both familial and sporadic forms of Parkinson's disease (PD), which has provided additional insights into the molecular pathways that underlie the condition. The detection of Parkinson's disease has become more accurate and timelier as a result of advancements in diagnostic procedures. The traditional method of diagnosis is mainly dependent on the clinical evaluation of motor symptoms; however, new advancements in imaging techniques, including as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have improved the capability of visualizing dopaminergic deficiencies in the brain [13], [14], [15], [16]. In addition to cerebrospinal fluid (CSF) and blood-based indicators, several imaging modalities are currently being investigated in order to increase the accuracy of early diagnosis and track the progression of the disease.

Parkinson's disease has been treated with a variety of different therapeutic techniques over the years. Pharmacological therapies, including as levodopa, dopamine agonists, and monoamine oxidase B inhibitors, continue to play a crucial role in the management of motor symptoms. However, the use of levodopa for an extended period of time can result in motor fluctuations and dyskinesias, which has prompted study into complementary and alternative treatments [16], [17], [18], [19]. Clinical trials have demonstrated that non-pharmacological treatments, such as deep brain stimulation (DBS), are effective in enhancing motor function and quality of life in individuals who have advanced Parkinson's disease (PD). Emerging research into gene therapy and stem cell therapy offers the possibility of future treatments by treating the genetic and cellular elements of the disease that are at the root of the condition [19], [20], [21].

3. METHODOLOGY

A comprehensive literature search was carried out in order to produce this study. The search was carried out utilizing major databases such as PubMed, Scopus, and Google Scholar. The goal was to compile a comprehensive collection of research studies that were relevant to the many different aspects of Parkinson's disease (PD). This included the pathophysiology of the disease, developments in diagnostic techniques, and treatment tactics. The key objective was to make certain that the study not only reflects the most recent developments in Parkinson's disease research but also offers a comprehensive overview of the current level of knowledge in this field.

Execution and planning of the search strategy were carried out with great care. The first step was to identify keywords that were associated with Parkinson's illness. These keywords included phrases such as "Parkinson's disease pathogenesis," "Parkinson's diagnostic methods," and "Parkinson's therapy advancements." Following the utilization of these keywords, the databases were searched in order to guarantee the inclusion of a wide variety of research that were pertinent. To further narrow the scope of the search, we concentrated on articles that had been subjected to peer review during the last ten years. The selection of this time span was necessary in order to guarantee that the review incorporates the most recent and relevant discoveries, which are reflective of the most recent developments and trends in Parkinson's disease research.

The criteria for inclusion in the selection of studies were based on a number of different aspects. Initially, it was necessary for studies to be subjected to peer review, which ensured that the research had been subjected to a thorough evaluation by professionals in the field. Additionally, studies were chosen because of their relevance to important features of Parkinson's disease, such as the pathophysiology of the disease, diagnostic tools, and treatment strategies. In order to contribute to a more complete understanding of Parkinson's disease, the objective was to incorporate studies that offered substantial insights into the aforementioned areas.

Following the identification of the studies that were pertinent, the procedure of data extraction started. In order to accomplish this, it was necessary to summaries the most important data from each study, recognize relevant patterns and trends, and assess the influence of recent developments in the treatment of Parkinson's disease. For instance, research on the etiology of Parkinson's disease was investigated in order to gain a better understanding of the underlying mechanisms and components that contribute to the development of the disease. This included study on the hereditary factors, environmental impacts, and cellular mechanisms that are involved in Parkinson's disease. The purpose of this review was to provide a comprehensive overview of the current understanding of the pathophysiology of Parkinson's disease by providing a summary of these results. Similar to this, studies on diagnostic advancements were analyzed in order to uncover novel approaches and technologies that can be utilized for the early and accurate identification of Parkinson's disease symptoms. Research on biomarkers, imaging techniques, and other diagnostic tools that have the potential to improve the identification and monitoring of Parkinson's disease were included in this field of study. The purpose of this study was to, through the presentation of these breakthroughs, emphasize the progress that has been made in the diagnosis of Parkinson's disease as well as the possibility for future improvements in this field.

In addition, the review concentrated on treatment methods for Parkinson's disease, providing a synopsis of current advancements in both pharmacological and non-pharmacological therapy. Studies on new drugs, surgical treatments, and lifestyle modifications that have been demonstrated to improve the management of Parkinson's disease symptoms were included in this category among the research that was conducted. In order to provide a complete overview of the various treatment choices that are currently available and the success of these alternatives in the management of Parkinson's disease, the review attempted to evaluate the impact that these improvements have had. Within the context of Parkinson's disease research, the synthesis of these findings was carried out in order to provide a comprehensive evaluation of the present level of existing information. Specifically, this entailed combining the most important data from a number of different studies in order to recognize recurring themes, trends, and gaps in the study. For instance, the review brought to light the necessity of conducting additional research on the mechanisms that underlie Parkinson's disease, as well as the development of diagnostic tools and treatment alternatives that are more efficient. The purpose of the assessment was to provide direction for future research and to highlight areas that require further exploration. This was accomplished by identifying these existing gaps. Additionally, the study investigated the significance of current discoveries for clinical practice, in addition to identifying research gaps that needed to be filled. This includes having a conversation about the ways in which different therapeutic tactics and diagnostic approaches could be incorporated into clinical practice in order to enhance the management of Parkinson's disease. The purpose of this review was to provide physicians and other healthcare professionals who are involved in the treatment of patients who have Parkinson's disease with an opportunity to gain useful insights by highlighting these implications. Overall, the review offered a complete overview of the present state of knowledge in Parkinson's disease research. It highlighted notable breakthroughs, identified research gaps, and discussed implications for future studies and clinical practice. A comprehensive summary was provided. The purpose of the review was to contribute to a better knowledge of Parkinson's disease and to help ongoing efforts to enhance the diagnosis and management of this devastating condition. This was accomplished by synthesizing the findings from a wide range of studies.

4. RESULTS AND DISCUSSION

The literature that was evaluated highlights important breakthroughs in the understanding of Parkinson's disease (PD), particularly in the areas of explaining the molecular basis of the disease, improving diagnostic tools, and creating new treatments. Recent study has provided further evidence that the aggregation of alpha-synuclein into Lewy bodies has a significant impact on neuronal function and survival [21], [22], [23], [24], [25]. This significance in the pathology of Parkinson's disease (PD) is wellestablished. Recent genetic findings have shed light on the etiology of Parkinson's disease (PD), shedding light on the ways in which mutations in genes like SNCA, LRRK2, and PINK1 contribute to both familial and sporadic forms of the disease.

As a result of breakthroughs in diagnostics, early detection and monitoring of Parkinson's disease have vastly improved [25], [26], [27]. In addition, ongoing research into biomarkers attempts to improve early diagnosis and disease tracking, while improved imaging techniques such as positron emission tomography (PET) and single-photon emission tomography (SPECT) give better visualization of dopaminergic deficiencies. Even though levodopa is the most effective treatment for motor symptoms, it frequently causes problems such as motor fluctuations and dyskinesias. Pharmacological treatments continue to be an essential component in the management of motor symptoms. Additional therapy alternatives have become available as a result of the development of non-pharmacological treatments and alternative pharmacological medicines, such as deep brain stimulation (DBS) [27], [28], [29], [30].

Emerging therapeutics, such as gene and stem cell treatments, offer the potential to bring about substantial advancements in the management of Parkinson's disease (PD). Stem cell treatment focuses on replacing injured neurons and restoring brain function, whereas gene therapy seeks to fix genetic flaws or introduce therapeutic genes. Gene therapy uses stem cells to accomplish these goals [30], [31], [32], [33], [34], [35]. There are still obstacles to overcome, such as the heterogeneity of diseases and the requirement for personalized treatments, despite the fact that these approaches seem promising. If we want to make progress in our understanding of Parkinson's disease (PD) and improve patient outcomes, it is crucial that we continue our research and collaborate across disciplines [36].

5. CONCLUSION

Recent research on Parkinson’s disease (PD) has led to significant progress in understanding its pathophysiology, enhancing diagnostic methods, and expanding treatment options. The role of alphasynuclein in PD pathology is well-documented, with genetic and environmental factors contributing to the disease's complexity. Advances in diagnostic techniques, including imaging and biomarkers, have improved early detection and monitoring, while pharmacological treatments and non-pharmacological interventions continue to play crucial roles in managing symptoms. Emerging therapies such as gene and stem cell treatments offer promising potential for future breakthroughs. However, challenges remain in addressing disease heterogeneity and developing personalized treatment approaches. Ongoing research and interdisciplinary efforts are vital for advancing Parkinson’s disease management and improving patient outcomes. The continuous evolution of our understanding and treatment of PD holds promise for more effective management strategies and, potentially, a cure.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors.

Author Contributions Statement

Name of AuthorCMSoVaFoIRDOEViSuPFu
Mohd Altaf Dar✓✓✓✓✓✓✓✓✓
Afshana Qadir✓✓✓✓✓✓✓✓
Zulfkar Qadrie✓✓✓✓✓✓✓✓✓✓
Humaira Ashraf✓✓✓✓✓✓✓✓✓

C: Conceptualization; M: Methodology; So: Software; Va: Validation; Fo: Formal analysis; I: Investigation; R: Resources; D: Data curation; O: Writing – original draft; E: Writing – review & editing; Vi: Visualization; Su: Supervision; P: Project administration; Fu: Funding acquisition.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

Not Applicable.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. [1] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and infertility: an update', International journal of adolescent medicine and health, vol. 34, pp. 1-9, July 2021. doi.org/10.1515/ijamh-2021-0073
  2. [2] R. J. Lihite et al., 'A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine', vol. 53, pp. 151-156, July 2017. doi.org/10.1016/j.ajme.2016.05.007
  3. [3] M. Zehravi and M. Maqbool, 'Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 339-345, June 2021. doi.org/10.1515/ijamh-2021-0058
  4. [4] M. Maqbool, F. Bekele, and G. Fekadu, 'Treatment strategies against triple-negative breast cancer: an updated review', Breast Cancer: Targets and Therapy, pp. 15-24, Jan. 2022. doi.org/10.2147/BCTT.S348060
  5. [5] S. Rasool and M. Maqbool, 'An overview about Hedychium spicatum: a review', vol. 9, pp. 476-480, Feb. 2019. doi.org/10.22270/jddt.v9i1-s.2429
  6. [6] M. Zehravi and M. Maqbool, 'Depression and anxiety in women with polycystic ovarian syndrome: a literature survey', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 367- 373, Aug. 2021. doi.org/10.1515/ijamh-2021-0092
  7. [7] M. Maqbool, I. Gani, and M. A. Dar, 'Anti-diabetic effects of some medicinal plants in experimental animals: a review', Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 1, pp. 66- 69, Feb. 2019. doi.org/10.22270/ajprd.v7i1.469
  8. [8] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and reproductive health of women: a curious association', International journal of adolescent medicine and health, vol. 33, pp. 333-337, Apr. 2021. doi.org/10.1515/ijamh-2021-0031
  9. [9] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, 'Polycystic ovary syndrome, a modern epidemic: an overview', Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019. doi.org/10.22270/jddt.v9i3.2661
  10. [10] M. Maqbool et al., 'An up to date on clinical prospects and management of osteoarthritis', Annals of Medicine and Surgery, vol. 72, Dec. 2021. doi.org/10.1016/j.amsu.2021.103077
  11. [11] A. Majeed, R. Bashir, S. Farooq, and M. Maqbool, 'Preparation, characterization and applications of nanoemulsions: An insight', Journal of Drug Delivery and Therapeutics, vol. 9, no. 2, pp. 520-527, Mar. 2019. doi.org/10.22270/jddt.v9i2.2410
  12. [12] M. Zehravi and M. Maqbool, 'Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review', Open Health, vol. 3, pp. 60-65, May 2022. doi.org/10.1515/openhe-2022-0008
  13. [13] R. Maqbool, M. Maqbool, and M. Zehravi, 'Menstrual distress in females of reproductive age: a literature review', International journal of adolescent medicine and health, vol. 34, pp. 11-17, July 2021. doi.org/10.1515/ijamh-2021-0081
  14. [14] I. Ara, M. Maqbool, G. Fekadu, T. A. Hajam, and M. A. Dar, 'Pharmaceutical significance of Nigella sativa L., a wonder herb', Journal of Applied Pharmaceutical Sciences and Research, vol. 3, no. 4, pp. 4-13, 2020. doi.org/10.31069/japsr.v3i4.2
  15. [15] M. Maqbool, N. Nasir, and S. Mustafa, 'Polycystic in ovarian syndrome and its various treatment strategies', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 5, no. 9, pp. 8470- 8478, Sept. 2018.
  16. [16] M. Maqbool, M. Zehravi, and R. Maqbool, 'Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital', India. CELLMED, vol. 11, no. 2, pp. 8-9, 2021.
  17. [17] I. Ara, M. Maqbool, B. Bukhari, and A. N. Hajam, 'Present status, standardization and safety issues with herbal drugs', International Journal of Research in Pharmaceutical Sciences and Technology, vol. 1, no. 3, pp. 95-101, May 2020. doi.org/10.33974/ijrpst.v1i3.169
  18. [18] I. Ara, M. Maqbool, and I. Gani, 'Reproductive Health of Women: implications and attributes', International Journal of Current Research in Physiology and Pharmacology, pp. 8-18, Nov. 2022.
  19. [19] M. Zehravi, R. Maqbool, and M. Maqbool, 'To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India', Journal of Pharmaceutical Research International, vol. 33, no. 31A, pp. 135-140, June 2021. doi.org/10.9734/jpri/2021/v33i31A31673
  20. [20] M. Maqbool, S. Javed, and A. A. Bajwa, 'Assessment OF pain management IN postoperative cases using different scales and questionnaires', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 6, no. 1, pp. 983-987, Jan. 2019.
  21. [21] I. Ara, M. Maqbool, and M. Zehravi, 'Psychic consequences of infertility on couples: A short commentary', Open Health, vol. 3, pp. 114-119, Jan. 2022. doi.org/10.1515/openhe-2022-0022
  22. [22] R. Bashir, M. Maqbool, and A. I. Zehravi, 'An In sight into Novel Drug Delivery System', In Situ Gels. CELLMED, vol. 11, no. 1, pp. 6-7, 2021.
  23. [23] M. Zehravi and M. Maqbool, 'Teenage menstrual dysfunction: an overview', International Journal of Adolescent Medicine and Health, vol. 35, no. 1, pp. 15-19, Sept. 2022. doi.org/10.1515/ijamh-2022-0018
  24. [24] I. Ara, M. Zehravi, M. Maqbool, and I. Gani, 'A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries', Journal of Pharmaceutical Research & Reports, no. 3, 2022.
  25. [25] M. Maqbool, W. Shabbir, and S. Aamir, 'Adverse events of blood transfusion and blood safety in clinical practice', Indo American Journal Of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.
  26. [26] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.
  27. [27] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
  28. [28] M. Maqbool, U. Ikram, and A. Anwar, 'Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders', Indo American Journal Of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8060-8065, Aug. 2018.
  29. [29] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
  30. [30] M. Zehravi and M. Maqbool, 'An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India', The Indian Journal of Nutrition and Dietetics, pp. 408-418, July 2021. doi.org/10.21048/IJND.2021.58.3.27285
  31. [31] M. Maqbool and M. Zehravi, 'Neuroprotective role of polyphenols in treatment of neurological disorders: A review', Interventional Pain Medicine and Neuromodulation, vol. 1, Dec. 2021. doi.org/10.5812/ipmn.117170
  32. [32] M. Maqbool and A. I. Gani, 'The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age', International Journal of Current Research in Physiology and Pharmacology, pp. 19-31, Nov. 2022.
  33. [33] M. Maqbool and I. Gani, 'Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review', Journal of Pharmacy Practice and Community Medicine, vol. 4, no. 4, 2018. doi.org/10.5530/jppcm.2018.4.46
  34. [34] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
  35. [35] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
  36. [36] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.

How to cite: Mohd Altaf Dar, Afshana Qadir, Zulfkar Qadrie, Humaira Ashraf (2024). Recent advances in understanding and treating Parkinson's disease. Journal Healthcare Treatment Development, 4(01), 122-129. https://doi.org/10.55529/jhtd.43.34.41

Copyright © 2024 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Published by HM Publishers.